<?xml version='1.0' encoding='UTF-8'?>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.3">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">NPJ Parkinsons Dis</journal-id>
      <journal-id journal-id-type="iso-abbrev">NPJ Parkinsons Dis</journal-id>
      <journal-title-group>
        <journal-title>NPJ Parkinson's Disease</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2373-8057</issn>
      <publisher>
        <publisher-name>Nature Publishing Group UK</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">35241697</article-id>
      <article-id pub-id-type="pmc">8894349</article-id>
      <article-id pub-id-type="publisher-id">285</article-id>
      <article-id pub-id-type="doi">10.1038/s41531-022-00285-z</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Aberrant dopamine transporter and functional connectivity patterns in <italic>LRRK2</italic> and <italic>GBA</italic> mutation carriers</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6182-0059</contrib-id>
          <name>
            <surname>Droby</surname>
            <given-names>Amgad</given-names>
          </name>
          <address>
            <email>amgadd@tlvmc.gov.il</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Artzi</surname>
            <given-names>Moran</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
          <xref ref-type="aff" rid="Aff4">4</xref>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lerman</surname>
            <given-names>Hedva</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
          <xref ref-type="aff" rid="Aff6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hutchison</surname>
            <given-names>R. Matthew</given-names>
          </name>
          <xref ref-type="aff" rid="Aff7">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bashat</surname>
            <given-names>Dafna Ben</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
          <xref ref-type="aff" rid="Aff4">4</xref>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Omer</surname>
            <given-names>Nurit</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gurevich</surname>
            <given-names>Tanya</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Orr-Urtreger</surname>
            <given-names>Avi</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cohen</surname>
            <given-names>Batsheva</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cedarbaum</surname>
            <given-names>Jesse M.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff8">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sapir</surname>
            <given-names>Einat Even</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
          <xref ref-type="aff" rid="Aff6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Giladi</surname>
            <given-names>Nir</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mirelman</surname>
            <given-names>Anat</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Thaler</surname>
            <given-names>Avner</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.413449.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 0518 6922</institution-id><institution>Movement Disorders Unit, Neurological Institute, </institution><institution>Tel Aviv Medical Center, </institution></institution-wrap>Tel Aviv, Israel </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.413449.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 0518 6922</institution-id><institution>Laboratory for Early Markers of Neurodegeneration, Neurological Institute, </institution><institution>Tel Aviv Medical Center, </institution></institution-wrap>Tel Aviv, Israel </aff>
        <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.12136.37</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0546</institution-id><institution>Sackler Faculty of Medicine, </institution><institution>Tel Aviv University, </institution></institution-wrap>Tel Aviv, Israel </aff>
        <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.12136.37</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0546</institution-id><institution>Sagol School of Neuroscience, </institution><institution>Tel Aviv University, </institution></institution-wrap>Tel Aviv, Israel </aff>
        <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.413449.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 0518 6922</institution-id><institution>Sagol Brain Institute, </institution><institution>Tel Aviv Sourasky Medical Center, </institution></institution-wrap>Tel Aviv, Israel </aff>
        <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.413449.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 0518 6922</institution-id><institution>Department of Nuclear Medicine, </institution><institution>Tel Aviv Sourasky Medical Center, </institution></institution-wrap>Tel Aviv, Israel </aff>
        <aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.417832.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0384 8146</institution-id><institution>Biogen Inc, </institution></institution-wrap>Cambridge, MA USA </aff>
        <aff id="Aff8"><label>8</label>Coeruleus Clinical Sciences LLC, Woodbridge, CT USA </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>3</day>
        <month>3</month>
        <year>2022</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>3</day>
        <month>3</month>
        <year>2022</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2022</year>
      </pub-date>
      <volume>8</volume>
      <elocation-id>20</elocation-id>
      <history>
        <date date-type="received">
          <day>22</day>
          <month>7</month>
          <year>2021</year>
        </date>
        <date date-type="accepted">
          <day>1</day>
          <month>2</month>
          <year>2022</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© The Author(s) 2022</copyright-statement>
        <license>
          <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
          <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p id="Par1">Non-manifesting carriers (NMCs) of Parkinson’s disease (PD)-related mutations such as <italic>LRRK2</italic> and <italic>GBA</italic> are at an increased risk for developing PD. Dopamine transporter (DaT)-spectral positron emission computed tomography is widely used for capturing functional nigrostriatal dopaminergic activity. However, it does not reflect other ongoing neuronal processes; especially in the prodromal stages of the disease. Resting-state fMRI (rs-fMRI) has been proposed as a mode for assessing functional alterations associated with PD, but its relation to dopaminergic deficiency remains unclear. We aimed to study the association between presynaptic striatal dopamine uptake and functional connectivity (FC) patterns among healthy first-degree relatives of PD patients with mutations in <italic>LRRK2</italic> and <italic>GBA genes</italic>. <italic>N</italic> = 85 healthy first-degree subjects were enrolled and genotyped. All participants underwent DaT and rs-fMRI scans, as well as a comprehensive clinical assessment battery. Between-group differences in FC within striatal regions were investigated and compared with striatal binding ratios (SBR). <italic>N</italic> = 26 <italic>GBA-</italic>NMCs, <italic>N</italic> = 25 <italic>LRRK2-</italic>NMCs, and <italic>N</italic> = 34 age-matched nonmanifesting noncarriers (NM-NCs) were included in each study group based on genetic status. While genetically-defined groups were similar across clinical measures, <italic>LRRK2</italic>-NMCs demonstrated lower SBR in the right putamen compared with NM-NCs, and higher right putamen FC compared to <italic>GBA</italic>-NMCs. In this group, higher striatal FC was associated with increased risk for PD. The observed differential SBR and FC patterns among <italic>LRRK2</italic>-NMCs and <italic>GBA</italic>-NMCs indicate that DaTscan and FC assessments might offer a more sensitive prediction of the risk for PD in the pre-clinical stages of the disease.</p>
      </abstract>
      <kwd-group kwd-group-type="npg-subject">
        <title>Subject terms</title>
        <kwd>Parkinson's disease</kwd>
        <kwd>Parkinson's disease</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>
            <institution>This study was funded by Biogen Inc.</institution>
          </funding-source>
        </award-group>
      </funding-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>© The Author(s) 2022</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <p id="Par2">Dopamine transporter (DaT)-single-photon emission computed tomography (DaTscan) is a sensitive imaging biomarker for early disease detection in Parkinson’s disease (PD)<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>, quantifying a membrane protein expressed exclusively in dopaminergic neurons<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. In PD, a dorso-posterior to a ventro-anterior gradient of striatal dopamine depletion occurs, with dopamine depletion in the premotor phase starting in the posterior putamen prior to changes in the caudate nucleus<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. Decreased striatal DaT uptake was detected among individuals with idiopathic rapid-eye-movement sleep behavior disorder (RBD), highlighting its’ role in the pre-motor phase of PD<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. Yet, while DaTscans are sensitive to striatal presynaptic DaT density, its spatio-temporal resolution remains rather limited<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR5">5</xref></sup>.</p>
      <p id="Par3">Resting-state functional MRI (rs-fMRI) enables the assessment of the inter-regional temporal correlations (functional connectivity [FC]) patterns reflecting spontaneous neural activity<sup><xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR7">7</xref></sup>. Previous rs-fMRI studies reported patterns of FC changes within cortical and subcortical functional networks of the brain in both PD patients and non-manifesting carriers (NMCs) of mutations in the <italic>LRRK2</italic> genes<sup><xref ref-type="bibr" rid="CR8">8</xref>–<xref ref-type="bibr" rid="CR14">14</xref></sup>.</p>
      <p id="Par4">Recent findings based on data from the Parkinson’s Progressive Marker Initiative (PPMI) study reported higher striatal binding ratios (SBR) in <italic>GBA-</italic> NMC compared with <italic>LRRK2</italic>- NMC and healthy controls<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. Therefore, understanding DaT downregulation and functional compensation dynamics in the preclinical phases of the disease is of great interest<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref></sup>.</p>
      <p id="Par5">In this study, we aimed to characterize presynaptic dopamine activity in NMC of mutations in the <italic>GBA</italic> and <italic>LRRK2</italic> genes using DaTscans and to investigate its association with striatal FC patterns in these genotypic groups.</p>
    </sec>
    <sec id="Sec2" sec-type="results">
      <title>Results</title>
      <sec id="Sec3">
        <title>Demographic and clinical characteristics of the study participants</title>
        <p id="Par6">Genetic phenotyping resulted in three study groups that consist of; <italic>N</italic> = 34 nonmanifesting noncarriers (NM-NC), <italic>N</italic> = 26 <italic>GBA</italic>-NMCs, and <italic>N</italic> = 25 <italic>LRRK2</italic>-NMCs. <italic>N</italic> = 74 (86%) were right-handed, <italic>N</italic> = 9 (10.5%) were left-handed, and <italic>N</italic> = 3 (3.5%) were ambidextrous. No significant differences were observed between the study groups in age, gender, H&amp;Y, handedness, UPDRS-III, UPDRS-total, MOCA, BDI, SCOPA-AUT, RBDq, NMS scores, and UPSIT scores (<italic>p</italic> &gt; 0.05; in all cases) (Table <xref rid="Tab1" ref-type="table">1</xref>). Both NMC groups showed higher, yet non–significant, mean LR compared to NM-NCs.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Demographic and clinical characteristics of the three study groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>NM-NC</th><th>GBA NM-MC</th><th>LRRK2 NM-MC</th><th><italic>p</italic>-value</th></tr></thead><tbody><tr><td>Age</td><td>53.55 ± 10.51</td><td>52.85 ± 8.81</td><td>50.52 ± 7.56</td><td>0.44<sup>a</sup></td></tr><tr><td>Gender (F/M)</td><td>18/16</td><td>12/14</td><td>13/12</td><td>0.91<sup>b</sup></td></tr><tr><td colspan="5">Handedness</td></tr><tr><td> ⁃ Right/left/ambidextrous</td><td>29/4/2</td><td>25/1/0</td><td>20/4/1</td><td>0.19<sup>c</sup></td></tr><tr><td>UPDRS-III</td><td>0.87 ± 1.26</td><td>0.61 ± 1.1</td><td>0.76 ± 2.05</td><td>0.86<sup>a</sup></td></tr><tr><td>UPDRS- Total</td><td>6.62 ± 5.32</td><td>4.50 ± 2.8</td><td>5.96 ± 5</td><td>0.26<sup>a</sup></td></tr><tr><td>MOCA</td><td>26.50 ± 2.68</td><td>26.69 ± 2.56</td><td>27.68 ± 2.68</td><td>0.28<sup>a</sup></td></tr><tr><td>UPSIT</td><td>31.39 ± 6.95</td><td>30.35 ± 7.42</td><td>37.12 ± 9.11</td><td>0.66<sup>a</sup></td></tr><tr><td>BDI</td><td>2.67 ± 6.21</td><td>5.28 ± 5.60</td><td>4.56 ± 4.77</td><td>0.08<sup>a</sup></td></tr><tr><td>SCOPA -AUT</td><td>7.03 ± 6.21</td><td>6.52 ± 7.00</td><td>7.18 ± 6.22</td><td>0.93<sup>a</sup></td></tr><tr><td>RBDq</td><td>2.00 ± 1.52</td><td>1.56 ± 2</td><td>1.43 ± 1.85</td><td>0.44<sup>a</sup></td></tr><tr><td>NMS</td><td>3.18 ± 3.20</td><td>2.80 ± 3.24</td><td>2.95 ± 1.92</td><td>0.88<sup>a</sup></td></tr><tr><td>LR</td><td>6.33 ± 17.00</td><td>11.38 ± 26.23</td><td>12.00 ± 26.00</td><td>0.57<sup>a</sup></td></tr><tr><td> ⁃ Low (&lt;70) [<italic>N</italic>, %]</td><td>34, 97%</td><td>24, 92%</td><td>23, 92%</td><td>–</td></tr><tr><td> ⁃ High (&gt;70) [<italic>N</italic>,%]</td><td>1, 3%</td><td>2, 8%</td><td>2, 8%</td><td>–</td></tr></tbody></table><table-wrap-foot><p>Unless otherwise stated, all values are expressed as mean ± SD.</p><p><sup>a</sup>1 × 3 ANOVA.</p><p><sup>b</sup><italic>χ</italic><sup>2</sup> test.</p><p><sup>c</sup>Kruskal-Wallis test. <italic>H&amp;Y</italic> Hohen &amp; Yahr stage, <italic>UPDRS</italic> Unified Parkinson’s disease rating scale, <italic>MOCA</italic> Montreal cognitive assessment. <italic>UPSIT</italic> university of Pennsylvania smell identification test, <italic>BDI</italic> Beck’s depression inventory, <italic>SCOPA-AUT</italic> Scale of Outcome in Parkinson’s disease Autonomic Dysfunction questionnaire, <italic>RBDq</italic> REM sleep behavior disorder questionnaire, <italic>NMS</italic> nonmotor symptoms questionnaire, <italic>LR</italic> likelihood ratio.</p></table-wrap-foot></table-wrap></p>
      </sec>
      <sec id="Sec4">
        <title>Between-groups differences in DaTscan SBRs</title>
        <p id="Par7">Between groups differences in the measured SBR values are summarized in Table <xref rid="Tab2" ref-type="table">2a</xref>. Significant differences in the right putamen were detected (1 × 3 ANOVA; <italic>F</italic><sub>(2,75)</sub>, <italic>p</italic> = 0.028). Based on the post-hoc analysis, <italic>LRRK2-</italic>NMCs had significantly lower SBR levels compared with NM-NCs in the right putamen (<italic>p</italic> = 0.037; Bonferroni-corrected). (See Fig. <xref rid="Fig1" ref-type="fig">1a</xref>). No significant differences were detected in the left putamen and bi-lateral caudate between the three study groups.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Measured DaTscan striatal binding ratio (SBR) and rs-fMRI functional connectivity (FC) values within striatal regions of interest (ROIs).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th rowspan="2">NM-NC</th><th rowspan="2">GBA-NMC</th><th rowspan="2">LRRK2-NMC</th><th rowspan="2"><italic>p</italic> value</th><th colspan="3">Post-hoc comparisons</th></tr><tr><th>NM-NC <italic>vs</italic>. GBA-NMC</th><th>NM-NC <italic>vs</italic>. LRRK2-NMC</th><th>GBA-NMC <italic>vs</italic>. LRRK2-NMC</th></tr></thead><tbody><tr><td colspan="8"><bold><italic>a. DaT- SBR</italic></bold></td></tr><tr><td>
<bold>L Caudate</bold></td><td>3.21 ± 0.38</td><td>3.21 ± 0.53</td><td>3.07 ± 0.46</td><td>0.481<sup>a</sup></td><td>–</td><td>–</td><td>–</td></tr><tr><td>
<bold>R Caudate</bold></td><td>3.17 ± 0.38</td><td>3.08 ± 0.52</td><td>3.07 ± 0.45</td><td>0.62<sup>a</sup></td><td>–</td><td>–</td><td>–</td></tr><tr><td>
<bold>L Putamen</bold></td><td>3.50 ± 0.44</td><td>3.48 ± 0.52</td><td>3.30 ± 0.50</td><td>0.31<sup>a</sup></td><td>–</td><td>–</td><td>–</td></tr><tr><td>
<bold>R Putamen</bold></td><td>3.39 ± 0.34</td><td>3.36 ± 0.52</td><td>3.08 ± 0.40</td><td>0.028<sup>a</sup></td><td>–</td><td>0.037<sup>b</sup></td><td>–</td></tr><tr><td>
<bold>Caudate asymmetry [%]</bold></td><td>3.68 ± 3.96</td><td>5.44 ± 4.91</td><td>5.38 ± 4.63</td><td>0.51<sup>a</sup></td><td>–</td><td>–</td><td>–</td></tr><tr><td>
<bold>Putamen asymmetry[%]</bold></td><td>6.41 ± 4.88</td><td>6.24 ± 5.46</td><td>9.35 ± 10.15</td><td>0.24<sup>a</sup></td><td>–</td><td>–</td><td>–</td></tr><tr><td colspan="8"><bold><italic>b. rs-fMRI-FC</italic></bold></td></tr><tr><td>
<bold>L Caudate</bold></td><td>3.12 ± 1.01</td><td>2.92 ± 0.85</td><td>3.87 ± 2.57</td><td>0.15<sup>a</sup></td><td>–</td><td>–</td><td>–</td></tr><tr><td>
<bold>R Caudate</bold></td><td>3.12 ± 1.01</td><td>2.82 ± 0.85</td><td>3.72 ± 2.37</td><td>0.14<sup>a</sup></td><td>–</td><td>–</td><td>–</td></tr><tr><td>
<bold>L Putamen</bold></td><td>2.61 ± 1.24</td><td>2.04 ± 0.82</td><td>3.04 ± 2.32</td><td>0.12<sup>a</sup></td><td>–</td><td>–</td><td>–</td></tr><tr><td>
<bold>R Putamen</bold></td><td>2.33 ± 1.22</td><td>1.84 ± 0.88</td><td>2.93 ± 2.11</td><td>0.05<sup>a</sup></td><td>–</td><td>–</td><td>0.05<sup>b</sup></td></tr></tbody></table><table-wrap-foot><p>Unless otherwise stated, all values are expressed as mean ± SD.</p><p><sup>a</sup>1 × 3 ANOVA.</p><p><sup>b</sup>Post-hoc comparisons (Bonferroni-corrected).</p></table-wrap-foot></table-wrap><fig id="Fig1"><label>Fig. 1</label><caption><title>Striatal binding ratios (SBRs) and functional connectivity (FC) levels measured in the three study groups.</title><p><bold>a</bold> Illustration of striatal regions of interest (ROIs) superimposed on a DaTscan image (<italic>left panel</italic>). Bar chart demonstrating between-group differences in calculated SBR within the striatal ROIs (<italic>right panel</italic>). <bold>b</bold> Illustration of striatal ROIs superimposed on calculated BGN spatial map (<italic>left panel</italic>). Bar chart demonstrating between-group differences in measured FC levels within the striatal ROIs (<italic>right panel</italic>). Bars represent the calculated group means, standard deviations (SD) are represented by the error bars.</p></caption><graphic xlink:href="41531_2022_285_Fig1_HTML" id="d32e1294"/></fig></p>
      </sec>
      <sec id="Sec5">
        <title>Between-groups differences in whole-basal ganglia network (BGN)</title>
        <p id="Par8">Compared to NM-NCs, <italic>LRRK2</italic>-NMC group showed significantly higher FC levels in the left caudate (<italic>p</italic> = 0.02, FWEc). Significantly higher FC levels were observed in the right thalamus in <italic>LRRK2-</italic>NMCs compared to <italic>GBA</italic>-NMCs (<italic>p</italic> = 0.01, FWEc) within the BGN as well. (See Fig. <xref rid="Fig2" ref-type="fig">2</xref> &amp; Supplementary Table <xref rid="MOESM1" ref-type="media">1)</xref>. No significant differences in other brain regions were further detected between the study groups.<fig id="Fig2"><label>Fig. 2</label><caption><title>Whole-brain between-group FC differences within the BGN.</title><p><bold>a</bold> Spatial distribution illustration of the calculated BGN network. <bold>b</bold> Significantly higher FC levels were observed in the left caudate in the <italic>LRRK2</italic> NMC group compared to the NM-NC group. <italic>LRRK2-</italic>NMCs showed increased FC in the right thalamus compared to <italic>GBA-</italic>NMCs (<italic>p</italic> &lt; 0.001, FWEc).</p></caption><graphic xlink:href="41531_2022_285_Fig2_HTML" id="d32e1349"/></fig></p>
      </sec>
      <sec id="Sec6">
        <title>Between-groups differences in striatal rs-fMRI FC levels</title>
        <p id="Par9">Table <xref rid="Tab2" ref-type="table">2b</xref> &amp; Fig. <xref rid="Fig1" ref-type="fig">1b</xref> demonstrate the measured intra<bold>-</bold>striatal FC levels in the three study groups. Significant differences in the right putamen were detected (1 × 3 ANOVA; <italic>F</italic><sub>(2,75)</sub>, <italic>p</italic> = 0.05). Based on the post-hoc comparisons, <italic>LRRK2</italic>-NMC demonstrated significantly higher FC levels in the right putamen compared to <italic>GBA</italic>-NMC (<italic>p</italic> = 0.05; Bonferroni-corrected).</p>
      </sec>
      <sec id="Sec7">
        <title>Association between DaTscan, FC, and likelihood ratio (LR)</title>
        <p id="Par10">Significant results of partial correlations accounting for age and gender between DaTscan metrics, FC, and LR scores in the three study groups are summarized in Fig. <xref rid="Fig3" ref-type="fig">3</xref>. In the NM-NC group, LR was negatively associated with SBR in the left putamen (<italic>r</italic> = −0.43, <italic>p</italic> = 0.026), right caudate (<italic>r</italic> = −0.43, <italic>p</italic> = 0.025), and right putamen (<italic>r</italic> = −0.53, <italic>p</italic> = 0.004). In the <italic>GBA</italic>-NMC group, negative associations between LR and SBR in the left caudate (<italic>r</italic> = −0.51, <italic>p</italic> = 0.05), left putamen (<italic>r</italic> = −0.77, <italic>p</italic> &lt; 0.001), and right putamen (<italic>r</italic> = −0.83, <italic>p</italic> &lt; 0.001) were observed (See Fig. <xref rid="Fig3" ref-type="fig">3a</xref>). Finally, in the <italic>LRRK2</italic>-NMC group, LR scores correlated positively with measured FC levels in the left caudate (<italic>r</italic> = 0.59, <italic>p</italic> = 0.02), left putamen (<italic>r</italic> = 0.56, <italic>p</italic> = 0.031), right caudate (<italic>r</italic> = 0.58, <italic>p</italic> = 0.024), and right putamen (<italic>r</italic> = 0.56, <italic>p</italic> = 0.029). In this group, no significant associations between the measured striatal FC levels and SBR were detected (Fig. <xref rid="Fig3" ref-type="fig">3b</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><title>Heat maps demonstrating significant correlation coefficients and <italic>p</italic>-values between LR scores, measured striatal SBRs, and FC levels.</title><p><bold>a</bold> Correlations between LR scores and striatal SBR in GBA-NMC and NM-NC groups. <bold>b</bold> Correlations between LR scores and striatal FC levels in the LRRK2-NMC group. The strength and direction of these associations are indicated by the color scale.</p></caption><graphic xlink:href="41531_2022_285_Fig3_HTML" id="d32e1484"/></fig></p>
      </sec>
      <sec id="Sec8">
        <title>Conversion to definite PD</title>
        <p id="Par11">Within the first three years since enrollment to the study, three participants (<italic>N</italic> = 2 <italic>GBA</italic>-NMC, and <italic>N</italic> = 1 <italic>LRRK2</italic> NMC) converted to clinically-definite PD. Baseline demographic and clinical characteristics of these participants are demonstrated in Supplementary Table <xref rid="MOESM1" ref-type="media">2</xref>. Both <italic>GBA</italic> converters were found to be 3 and 1 SD below the groups’ mean in regards to measured mean striatal SBR respectively. The <italic>LRRK2-</italic>NMC converter was found to be 0.5 SD below the groups’ mean in this measure. In intra-striatal FC level, the <italic>GBA</italic> converters were 2 and 1 SD below the groups’ intra-striatal mean FC level. Similarly, the <italic>LRRK2</italic>-NMC converter was found to be 1 SD below the <italic>LRRK2</italic>-NMC groups’ mean (See Fig. <xref rid="Fig4" ref-type="fig">4</xref> &amp; Supplementary Table <xref rid="MOESM1" ref-type="media">2</xref>).<fig id="Fig4"><label>Fig. 4</label><caption><title>Dot plots of mean striatal SBR (left panel) and FC levels (right panel) in the study groups.</title><p>Grey dots denote those that converted to definite PD.</p></caption><graphic xlink:href="41531_2022_285_Fig4_HTML" id="d32e1538"/></fig></p>
      </sec>
    </sec>
    <sec id="Sec9" sec-type="discussion">
      <title>Discussion</title>
      <p id="Par12">Subtle nigrostriatal dopaminergic pathways dysfunction has been documented in the prodromal phase of PD leading to sub-clinical motor symptoms<sup><xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR18">18</xref></sup>. Neuroimaging plays an important role in investigating changes in these pathways occurring during this phase<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. This was a single-site study, where we performed a combined DaTscan and rs-fMRI analysis of data collected from <italic>GBA-</italic>NMC and <italic>LRRK2</italic>-NMC to explore the interplay between SBR levels and regional FC in the striatum in individuals at increased risk for PD. Using multi-modality neuroimaging methods, distinct group-specific patterns were observed.</p>
      <p id="Par13"><italic>LRRK2</italic>-NMCs showed significantly reduced striatal SBR in the right putamen compared to the NM-NCs study group, while no significant differences in the measured DaTscan SBRs in the <italic>GBA</italic>-NMCs group compared to NM-NCs were observed. This is in line with recent findings which demonstrated striatal SBR alterations in the pre-clinical stage of the disease<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. This study further reported a significant SBR increase among <italic>GBA</italic>-NMCs compared to <italic>LRRK2-</italic> NMCs, and NM-NCs<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. We observed higher left and right putamen SBR among <italic>GBA</italic>-NMCs and <italic>LRRK2</italic>-NMCs, however, these did not reach statistical significance. Discrepancies between the findings of both studies could be attributed to several factors including, the smaller cohort size of the current study, different methodologies used for SBR calculation, and mutation types dissimilarities included within the <italic>GBA</italic>-NMCs group. Nevertheless, this finding highlights the differential degenerative processes affecting striatal dopaminergic neurons among the different genetic groups<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>, possibly suggesting that increased striatal DaT binding in <italic>GBA</italic>-NMCs carriers might reflect compensatory regulatory alterations and DaT downregulation, leading to increased striatal dopaminergic activity<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>.</p>
      <p id="Par14">In rs-fMRI, <italic>LRRK2</italic>-NMCs demonstrated higher intra-network regional FC levels within the left caudate compared to NM-NCs, and within the left thalamus compared to the <italic>GBA</italic>-NMCs group. This is consistent with recent findings demonstrating increased within network connectivity in PD patients with <italic>LRRK2</italic> mutation compared to sporadic and <italic>GBA</italic> patients<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. However, correction for multiple comparisons on the whole brain level in the BGN between-group comparisons renders this to be less sensitive for detecting subtle changes taking place in the prodromal phase. This is evident based on the results of region-specific ROI analysis demonstrating higher FC levels in the caudate and putamen in the <italic>LRRK2</italic>-NMCs group compared to NM-NC and <italic>GBA-</italic>NMC groups. Opposed to the fact that no significant differences were observed in the measured FC levels within the striatal ROIs between NM-NC and <italic>LRRK2</italic>-NMCs; measured FC levels within the right putamen in this group were found to be significantly higher compared to the <italic>GBA</italic>-NMCs group. It was recently reported that in contrast to <italic>LRRK2</italic>-PD, <italic>GBA</italic>-PD demonstrate FC increases outside the core networks involving cortico-cortical pathways<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. In a previous study, we demonstrated increased FC and regional activity among <italic>LRRK2-</italic>NMCs as compared to controls while performing motor and cognitive tasks, possibility reflecting compensatory mechanisms<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR20">20</xref>–<xref ref-type="bibr" rid="CR22">22</xref></sup>. Such observed patterns of FC alterations were suggested to represent surrogate markers of the more aggressive clinical course of PD in <italic>GBA</italic> mutation carriers<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>.</p>
      <p id="Par15">Increased frontoparietal and fronto-limbic FC, and preserved striatal dopamine uptake were found to be associated with better cognitive performance in PD and patients with Lewy body diseases<sup><xref ref-type="bibr" rid="CR23">23</xref>,<xref ref-type="bibr" rid="CR24">24</xref></sup>, reflecting patterns of compensatory mechanisms minimizing clinical deficits. However, little information is available on the relationship between DaT and FC patterns in individuals at risk for PD. When investigating the relationship between the MDS probability scores, DaTscan, and rs-fMRI FC parameters, an interesting parity was detected. In both <italic>GBA-</italic>NMCs and NM-NCs groups, higher LR scores were found to correlate negatively with lower DaT binding, while in <italic>LRRK2</italic>-NMC, higher LR scores correlated positively with the measured striatal FC levels. These findings might indicate differential susceptibility of various midbrain structures to PD pathophysiology<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>. Previous studies demonstrated evidence of terminal losses in the pre-symptomatic phase among <italic>LRRK2</italic>-NMCs<sup><xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR27">27</xref></sup>. Based on these findings, we believe that phenotype-specific compensatory mechanisms allow <italic>LRRK2</italic>-NMCs to maintain clinical functions, as the reduction of DaT binding in the right putamen was associated with increased regional FC in the striatum. A recent PET study by Wile et al.<sup><xref ref-type="bibr" rid="CR28">28</xref></sup> described candidate cellular compensatory mechanisms in both <italic>LRRK2</italic> PD patients and <italic>LRRK2-</italic>NMCs that might underlie the milder [disease] progression time course. In this study, the authors reported elevated serotonin transporter binding in <italic>LRRK2-</italic>NMCs<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>. This might be indicative of increased serotonin neurons density, regulatory changes in synaptic terminal density, or transporter expression. Thus, reactive or compensatory sprouting of serotonergic terminals in the striatum might occur gradually over a prolonged period and possibly contribute to the preservation of dopamine synthesis in <italic>LRRK2-</italic>NMCs<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>.</p>
      <p id="Par16">The laterality effects observed in this study as well as in others are worthwhile mentioning. As the mechanisms generating asymmetry in the prodromal phase of PD are yet not fully clear, two candidate mechanisms are proposed. Firstly, the number of nigral neurons differs from one side to another from birth; hence, the side with a reduced number of neurons reaches the threshold of clinical manifestation earlier<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. Alternatively, nigral neurons might show heightened vulnerability on one side compared to the other. Therefore, a subtle ongoing degenerative process will result in a marked difference in the vulnerable side<sup><xref ref-type="bibr" rid="CR29">29</xref>,<xref ref-type="bibr" rid="CR30">30</xref></sup>. Based on our finding, the latter is more plausible, especially in the putamen, where the NM-NCs showed greater SBR compared to the contralateral side. This is further highlighted in the <italic>LRRK2</italic>-NMCs group where SBR in the right putamen was markedly lower than that measured on the left side.</p>
      <p id="Par17">In <italic>GBA</italic>, a multimodality PET study investigating the neurobiology of PD reported no dopamine synthesis reduction in the striatum in asymptomatic <italic>GBA</italic>-NMCs compared with healthy controls<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. The authors of this study concluded that <italic>GBA</italic> mutations alone were not predictive for dopamine pathology; rather, other genetic and /or environmental factors most likely act in concert with the disease risk<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. This further corroborates our findings, as well as those reported by Simuni et al.<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>, wherein <italic>GBA</italic>-NMCs, the maintained SBR together with reduced striatal FC based on rs-fMRI may be indicative of the limited neural reserve in these individuals.</p>
      <p id="Par18">The current study reports only cross-sectional data of an ongoing longitudinal study following up <italic>GBA</italic>-NMCs, <italic>LRRK2</italic>-NMCs, and NM-NCs first-degree relatives of PD patients for five years. Within the first three years following enrollment in this study, three NMCs converted to definite PD. Both <italic>GBA-</italic>NMCs converters were found to have higher LR scores as well as low striatal SBR at baseline, while the <italic>LRRK2</italic>-NMCs converter showed to have relatively low LR and mean striatal FC levels. This low LR could be attributed to the fact that DaTscan derived metrics were not included in the LR calculation, leading to LR under-estimation. Additionally, simultaneous DaTscan and MRI imaging acquisition will contribute greatly in canceling out the effects of possible confounders occurring during the elapsed time between both acquisitions, further enhancing the sensitivity for the spatial and temporal relationship between striatal DaT and FC. It is nevertheless worthwhile acknowledging the potential drawbacks of rs-fMRI-based measures. Relying on the BOLD response, FC parameters might be susceptible to several endogenous and exogenous factors that contribute to signal variability<sup><xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR32">32</xref></sup>. These include hormonal effects, blood pressures, body mass index, circadian rhythm, sleep duration, and other vascular parameters<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. Adherence to standardized acquisition methods would help to minimize these inherit confounders in rs-fMRI measurements.</p>
      <p id="Par19">Future findings from the follow-up data, and in larger sample sizes would allow for further insights regarding the temporal dynamics between striatal DaT, FC patterns, and clinical performance scores in the prodromal phase of the disease.</p>
      <p id="Par20">In summary, the present findings indicate that differential DaT-FC patterns can be observed among the genotypic groups in prodromal PD. These findings warrant further investigations examining the contribution of FC measures to the sensitivity of conversion prediction to definite PD in individuals at high risk.</p>
    </sec>
    <sec id="Sec10">
      <title>Methods</title>
      <sec id="Sec11">
        <title>Study participants</title>
        <p id="Par21">This study is part of the ongoing BEAT-PD observational study taking place at the Tel Aviv Sourasky Medical Center (TASMC). In total, 89 healthy individuals aged ≥ 40 years were included in this study if they had a first-degree relation to PD and did not fulfill the UK PD Brain Bank criteria for PD. Exclusion criteria were as follows: (i) diagnosed neurological or psychiatric disorder, (ii) a malignancy, (iii) HIV, HBV or HCV positive, (iv) claustrophobia and/or other MRI related contraindication. Of those four participants were excluded from MRI scanning due to contraindications (surgical hardware, tattoos/permanent makeup). No significant incidental findings were reported that would lead to excluding further participants from the analysis based on the neuro-radiological assessment of T2-FLAIR images of all participants. All enrolled participants were genotyped for the G2019S-<italic>LRRK2</italic> mutation and 9 common mutations in the <italic>GBA</italic> gene; N370S, R496H, L444P, 84GG, IVS2 + 1G- &gt; A, V394L, 370Rec, and E326K and T369M. This study was approved by the institutional review board (IRB) at the Tel Aviv Sourasky Medical Center. All subjects gave their informed written consent upon participation.</p>
      </sec>
      <sec id="Sec12">
        <title>Clinical assessments</title>
        <p id="Par22">Demographic data including a complete medical history was collected from all participants. Participants underwent comprehensive assessment using the following tools: the MDS-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. The Montreal Cognitive Assessment (MOCA) for global cognitive functions<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>, the Beck Depression Inventory (BDI) for mood assessment<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>. The Non-Motor Symptoms Questionnaire (NMSQ)<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>, the Scale of Autonomic Function in PD (SCOPA-AUT)<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>, and the REM sleep Behavior Disorder Questionnaire (RBDq)<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>. Olfaction was tested using the University of Pennsylvania Smell Identification Test (UPSIT)<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>.</p>
      </sec>
      <sec id="Sec13">
        <title>Likelihood ratio (LR) calculation</title>
        <p id="Par23">The above described clinical measures were used for calculating individualized risk for PD as likelihood ratios (LR) based on the 2019 updated MDS research criteria for prodromal PD; excluding PET/SPECT dopaminergic markers<sup><xref ref-type="bibr" rid="CR40">40</xref>,<xref ref-type="bibr" rid="CR41">41</xref></sup>. Each subject was allocated a ratio between 0 and 100% for risk of prodromal PD. LR above &gt;70% was considered as high-risk for PD.</p>
      </sec>
      <sec id="Sec14">
        <title>Imaging</title>
        <sec id="Sec15">
          <title>DaTscan acquisition</title>
          <p id="Par24">Before tracer injection, subjects received stable iodine orally (7–10 drops of a saturated solution of potassium iodide) to reduce uptake and radiation exposure of the thyroid gland. 5 mCi (185MBq) of <sup>123</sup>ioflupane (DaTScan<sup>TM</sup>) was then injected intravenously. Single Photon Emission Tomography (SPECT) acquisition was initiated 3 h post-injection using an Infinia camera (GE Healthcare) with a fan beam collimator. The acquisition protocol was 128 × 128 matrix size and 20 s per frame. Data were reconstructed as following ordered subset expectation maximization with 2 iterations and 10 subsets, attenuation correction with coefficient 0.11, and Butterworth 0.5 Hz filtering with the critical frequency of 0.5 and power 10. No scatter correction was applied.</p>
        </sec>
        <sec id="Sec16">
          <title>MRI acquisition</title>
          <p id="Par25">MR data were acquired using a 3-T Magnetom Prisma<sup>®</sup> (Siemens, Erlangen, Germany) MR scanner equipped with a 20 channel phased-array head coil. The MRI protocol included: (1) a high resolution 3D magnetization-prepared rapid gradient echo (MP-RAGE) T1-weighted sequence (TR/TE/TI = 2200/3.22/1100 ms; FA = 9°, voxel size = 1 × 1 × 1 mm<sup>3</sup>, acquisition time: 5:06 min.), (2) axial T2-fluid attenuated inversion recovery (FLAIR) (TR/TE/TI = 8000/117/2370 ms; FA = 150°; voxel size = 0.8 × 0.8 × 5 mm<sup>3</sup>, acquisition time: 2:58 min.), and (3) eyes open 144 volumes resting-state fMRI datasets using single-shot echo-planar imaging (EPI) sequence (TR/TE = 2500/30 ms; FA = 90°, FoV = 220 × 220 mm; 42 axial slices with no gap, voxel size = 2.3 × 2.3 × 3 mm<sup>3</sup> with no gap, acquisition time = 6:08 min). The DaT-scan and MRI scans were performed on within 6 ± 4 weeks of each other with no specific order.</p>
        </sec>
      </sec>
      <sec id="Sec17">
        <title>DaTscan processing</title>
        <p id="Par26">All imaging analyses were performed using SPM12 (<ext-link ext-link-type="uri" xlink:href="https://www.fil.ion.ucl.ac.uk/spm/software/spm12/">https://www.fil.ion.ucl.ac.uk/spm/software/spm12/</ext-link>). DaTscan data processing included realignment of the DaT-SPECT images to FP-CIT standard template<sup><xref ref-type="bibr" rid="CR42">42</xref></sup> using rigid-body transformation and spatial normalization. For SBR calculations, intensity was normalized relative to the occipital lobe which served as a reference area<sup><xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR27">27</xref></sup>. The reference area was defined in each subject based on the MNI structural atlas. Finally, atlas-based (Harvard-Oxford atlas, <ext-link ext-link-type="uri" xlink:href="http://cma.mgh.harvard.edu">http://cma.mgh.harvard.edu</ext-link>) masks for the caudate and putamen were applied to the subjects’ DaTscan images to extract mean SBR values within striatal regions of interest (ROIs) (See Supplementary Fig. <xref rid="MOESM1" ref-type="media">1</xref>). SBR values were calculated as described in Koh et al., 2016<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>. SBR asymmetry indices were calculated as follows:<disp-formula id="Equa"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{\mathrm{Asym}}}}{{{\mathrm{.}}}}\;{{{\mathrm{Index}}}} = \frac{{|\left( {SBR_{left} - SBR_{right}} \right)|}}{{\left( {SBR_{left} + SBR_{right}} \right) \ast 0.5}} \times 100$$\end{document}</tex-math><mml:math id="M2"><mml:mrow><mml:mi mathvariant="normal">Asym</mml:mi><mml:mi mathvariant="normal">.</mml:mi><mml:mspace width="0.16em"/><mml:mi mathvariant="normal">Index</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mo>∣</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mi>S</mml:mi><mml:mi>B</mml:mi><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mi>S</mml:mi><mml:mi>B</mml:mi><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>g</mml:mi><mml:mi>h</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:mo>∣</mml:mo></mml:mrow><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mi>S</mml:mi><mml:mi>B</mml:mi><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>S</mml:mi><mml:mi>B</mml:mi><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>g</mml:mi><mml:mi>h</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:mo>*</mml:mo><mml:mn>0.5</mml:mn></mml:mrow></mml:mfrac><mml:mo>×</mml:mo><mml:mn>100</mml:mn></mml:mrow></mml:math><graphic xlink:href="41531_2022_285_Article_Equa.gif" position="anchor"/></alternatives></disp-formula>Where the obtained asymmetry index reflects the percentage of deviation from the average ROI SBR of both sides<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>. The calculated SBR values for the striatal ROIs as described above were compared with those obtained from the GE<sup>®</sup> clinical software using inter-class correlation for absolute agreement. High agreement between measured SBR values in the investigated striatal regions was obtained using both approaches (ICC = 0.7-0.9, <italic>p</italic> &lt; 0.0001) (See Supplementary Fig. <xref rid="MOESM1" ref-type="media">2</xref>).</p>
      </sec>
      <sec id="Sec18">
        <title>MRI data processing</title>
        <p id="Par27">For rs-fMRI datasets, the first 4 time frames (~12 s) were removed to allow the MR signal to achieve T1 equilibrium. The following steps were applied: Slice time correction, re-alignment to the first volume image in order to correct for head movement, frames of high inter-frame displacement (&gt;3–3.5 mm) were disregarded from further analysis. Normalization to MNI space using the forward transformation parameters obtained from DARTEL procedure was then carried out, and smoothing using an 8 mm FWHM kernel. The de-noising and filtering of pre-processed rs-fMRI data sets were analyzed using the CONN (v.17) toolbox (McGovern Institute for Brain Research, Massachusetts Institute of Technology, Cambridge; <ext-link ext-link-type="uri" xlink:href="https://web.conn-toolbox.org/">https://web.conn-toolbox.org/</ext-link>), where, linear de-trending, temporal de-spiking, band-pass filtering (0.01 –0.08 Hz) were carried out after regression. The subjects’ six head-motion parameters, white matter (WM), and cerebrospinal fluid (CSF) signal time-course were entered as covariates of no interest in the regression model. Striatal network calculation was performed by CONN toolbox. Here, group-level independent component analysis (ICA) with 20 independent components (IC) approach was used. Individual subject-level functional networks were obtained by GICA1 back-reconstruction<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>. The basal ganglia functional (BGN) network was identified based on dice coefficients (ICC) for best spatial overlap with a default template provided by CONN as well as based on visual inspection for verification of spatial accuracy (IC = 20, see Szewczk-Krolikowski et al.<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>). Additionally, FC levels within striatal regions were assessed in order to match the performed DaTscan analysis. The caudate and putamen masks were applied to the first-level BGN spatial maps of each subject to extract mean FC beta-weights for all subjects.</p>
      </sec>
      <sec id="Sec19">
        <title>Statistical analysis</title>
        <p id="Par28">Statistical analysis was computed for all measures of interest using SPSS<sup>®</sup>, v22 (IBM, Chicago, USA). One-way analysis of variance (1 × 3 ANOVA) was used to probe differences between the study groups in continuous measures (e.g. Age, H&amp;Y, UPDRS-III, UPDRS-total, MOCA, UPSIT, BDI, SCOPA-AUT, RBDQ, NMS, and LR). Between-group gender differences were assessed using chi-square (χ<sup>2</sup>). Whole-brain between-group differences in the BGN were carried out using 1 × 3 ANOVA in SPM. For this comparison, a cut-off threshold of <italic>p</italic> &lt; 0.001 adjusted for cluster size (FWE<italic>c</italic>) based on AlphaSim calculations (cluster size &gt; 70 voxels) was used. 1 × 3 ANOVA was also applied to probe the between-group differences in SBR and FC values measures within the striatal between the study groups. Partial correlations accounting for age and gender (with bootstrapping 1000 samples) were performed to probe the relationship between LR scores and the measured SBR, and FC levels in the striatal ROIs based on DaTscan and rs-fMRI, within the study groups. The significance threshold of <italic>p</italic> &lt; 0.05 Bonferroni-corrected for multiple comparisons was adopted for all conducted comparisons.</p>
      </sec>
      <sec id="Sec20">
        <title>Reporting summary</title>
        <p id="Par29">Further information on research design is available in the <xref rid="MOESM2" ref-type="media">Nature Research Reporting Summary</xref> linked to this article.</p>
      </sec>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Supplementary information</title>
      <sec id="Sec21">
        <p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41531_2022_285_MOESM1_ESM.pdf"><caption><p>Supplemental Materials</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="41531_2022_285_MOESM2_ESM.pdf"><caption><p>Reporting Summary</p></caption></media></supplementary-material>
</p>
      </sec>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p><bold>Publisher’s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
      </fn>
    </fn-group>
    <sec>
      <title>Supplementary information</title>
      <p>The online version contains supplementary material available at 10.1038/s41531-022-00285-z.</p>
    </sec>
    <ack>
      <title>Acknowledgements</title>
      <p>The authors wish to thank all study participants for their devoted participation in this study. We also thank Prof. Talma Hendler and Tal Koslovski for supporting this work. This study was funded by Biogen Inc. (grant #20416).</p>
    </ack>
    <notes notes-type="author-contribution">
      <title>Author contributions</title>
      <p>A.D. Study conception and execution, statistical design and execution, writing of first draft. M.A.: Statistical review and critique, Manuscript review and critique. H.L.: Data collection, manuscript review and critique. R.M.H.: Manuscript review and critique. D.B.B.: Manuscript review and critique. N.O.: Data collection. T.G.: Manuscript review and critique. A.O.U.: Manuscript review and critique. B.C.: Data collection. J.M.C.: Manuscript review and critique. E.E.S.: Manuscript review and critique. N.G.: Manuscript review and critique. A.M.: Study organization, manuscript review and critique. A.T.: Study conception, data collection, writing of first draft, review and critique.</p>
    </notes>
    <notes notes-type="data-availability">
      <title>Data availability</title>
      <p>De-identified data supporting the findings reported in this work will be available by the corresponding author upon reasonable request by researchers who meet the criteria for access to confidential data (i.e., affiliated to research institution/ hospital).</p>
    </notes>
    <notes id="FPar1" notes-type="COI-statement">
      <title>Competing interests</title>
      <p id="Par30">A.D., M.A., H.L., D.B.B., N.O., A.O.U., B.C., E.E.S. report no competing interests. T. Gurevich reports no competing interests relevant to this work. She received advisory board membership with honoraria to her and her institution from Abbvie Israel, Neuroderm Ltd. and Allergan. She recieves research support from Phonetica Ltd., Israeli Innovation Authority, Sagol School of Neuroscience (Brain Boost), and Parkinson’s Foundation. She received travel support from Abbvie, Allergan, Medisson, and Medtronic. RM. Huchison is an employee of and owns stock in Biogen. J.M. Cedarbaum is a former employee of Biogen, and reports no competing interests relevant to this work. N. Giladi has no competing interests pertaining to this work. He serves as a member of the editorial board for the Journal of Parkinson’s Disease. He serves as consultant to Sionara, Accelmed, Teva, NeuroDerm, Intec Pharma, Pharma2B, Denali and Abbvie. He received royalties from Lysosomal Therapeutics (LTI) and payment for lectures at Teva, UCB, Abbvie, Sanofi-Genzyme, Bial, and Movement Disorder Society. He received research support from the Michael J Fox Foundation, the National Parkinson Foundation, the European Union 7th Framework Program, and the Israel Science Foundation as well as from Teva NNE program, Biogen, LTI, and Pfizer. A. Mirelman reports no competing interests relevant to this work. She reports serving as advisor to Neuroderm. A. Thaler reports receiving honoraria from Abbvie- Israel. He reports no competing interests relevant to this work.</p>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>CS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson’s disease</article-title>
          <source>Ann. Neurol.</source>
          <year>2000</year>
          <volume>47</volume>
          <fpage>493</fpage>
          <lpage>503</lpage>
          <pub-id pub-id-type="pmid">10762161</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Miller</surname>
              <given-names>GW</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Immunochemical analysis of dopamine transporter protein in Parkinson’s disease</article-title>
          <source>Ann. Neurol.</source>
          <year>1997</year>
          <volume>41</volume>
          <fpage>530</fpage>
          <lpage>539</lpage>
          <pub-id pub-id-type="pmid">9124811</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Iranzo</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Electroencephalographic slowing heralds mild cognitive impairment in idiopathic REM sleep behavior disorder</article-title>
          <source>Sleep. Med</source>
          <year>2010</year>
          <volume>11</volume>
          <fpage>534</fpage>
          <lpage>539</lpage>
          <pub-id pub-id-type="pmid">20462792</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rahmim</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Zaidi</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>PET versus SPECT: strengths, limitations and challenges</article-title>
          <source>Nucl. Med. Commun.</source>
          <year>2008</year>
          <volume>29</volume>
          <fpage>193</fpage>
          <lpage>207</lpage>
          <pub-id pub-id-type="pmid">18349789</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <mixed-citation publication-type="other">Palermo, G. &amp; Ceravolo, R. Molecular Imaging of the Dopamine Transporter. <italic>Cells</italic><bold>8</bold>, 872 (2019).</mixed-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Biswal</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Yetkin</surname>
              <given-names>FZ</given-names>
            </name>
            <name>
              <surname>Haughton</surname>
              <given-names>VM</given-names>
            </name>
            <name>
              <surname>Hyde</surname>
              <given-names>JS</given-names>
            </name>
          </person-group>
          <article-title>Functional connectivity in the motor cortex of resting human brain using echo-planar MRI</article-title>
          <source>Magn. Reson Med</source>
          <year>1995</year>
          <volume>34</volume>
          <fpage>537</fpage>
          <lpage>541</lpage>
          <pub-id pub-id-type="pmid">8524021</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fox</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Raichle</surname>
              <given-names>ME</given-names>
            </name>
          </person-group>
          <article-title>Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging</article-title>
          <source>Nat. Rev. Neurosci.</source>
          <year>2007</year>
          <volume>8</volume>
          <fpage>700</fpage>
          <lpage>711</lpage>
          <pub-id pub-id-type="pmid">17704812</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Helmich</surname>
              <given-names>RC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Spatial remapping of cortico-striatal connectivity in Parkinson’s disease</article-title>
          <source>Cereb. Cortex</source>
          <year>2010</year>
          <volume>20</volume>
          <fpage>1175</fpage>
          <lpage>1186</lpage>
          <pub-id pub-id-type="pmid">19710357</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tessitore</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Resting-state brain connectivity in patients with Parkinson’s disease and freezing of gait</article-title>
          <source>Parkinsonism Relat. Disord.</source>
          <year>2012</year>
          <volume>18</volume>
          <fpage>781</fpage>
          <lpage>787</lpage>
          <pub-id pub-id-type="pmid">22510204</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tessitore</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Default-mode network connectivity in cognitively unimpaired patients with Parkinson disease</article-title>
          <source>Neurology</source>
          <year>2012</year>
          <volume>79</volume>
          <fpage>2226</fpage>
          <lpage>2232</lpage>
          <pub-id pub-id-type="pmid">23100395</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Helmich</surname>
              <given-names>RC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers</article-title>
          <source>Neurology</source>
          <year>2015</year>
          <volume>84</volume>
          <fpage>399</fpage>
          <lpage>406</lpage>
          <pub-id pub-id-type="pmid">25540317</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Postuma</surname>
              <given-names>RB</given-names>
            </name>
          </person-group>
          <article-title>Resting state MRI: a new marker of prodromal neurodegeneration?</article-title>
          <source>Brain</source>
          <year>2016</year>
          <volume>139</volume>
          <fpage>2106</fpage>
          <lpage>2108</lpage>
          <pub-id pub-id-type="pmid">27457227</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jacob</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Network abnormalities among non-manifesting Parkinson disease related LRRK2 mutation carriers</article-title>
          <source>Hum. Brain Mapp.</source>
          <year>2019</year>
          <volume>40</volume>
          <fpage>2546</fpage>
          <lpage>2555</lpage>
          <pub-id pub-id-type="pmid">30793410</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vilas</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Nigral and Striatal Connectivity Alterations in Asymptomatic LRRK2 Mutation Carriers: A Magnetic Resonance Imaging Study</article-title>
          <source>Mov. Dis.</source>
          <year>2016</year>
          <volume>31</volume>
          <fpage>1820</fpage>
          <lpage>1828</lpage>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Simuni</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson’s Progression Markers Initiative (PPMI): a cross-sectional study</article-title>
          <source>Lancet Neurol.</source>
          <year>2020</year>
          <volume>19</volume>
          <fpage>71</fpage>
          <lpage>80</lpage>
          <pub-id pub-id-type="pmid">31678032</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kägi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bhatia</surname>
              <given-names>KP</given-names>
            </name>
            <name>
              <surname>Tolosa</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>The role of DAT-SPECT in movement disorders</article-title>
          <source>J. Neurol. Neurosurg. Psychiatry</source>
          <year>2010</year>
          <volume>81</volume>
          <fpage>5</fpage>
          <lpage>12</lpage>
          <pub-id pub-id-type="pmid">20019219</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <mixed-citation publication-type="other">Schaeffer, E., Postuma, R. B. &amp; Berg, D. Chapter 10 - Prodromal PD: A new nosological entity. in <italic>Progress in Brain Research</italic> (eds. Björklund, A. &amp; Cenci, M. A.) vol. 252 331–356 (Elsevier, 2020).</mixed-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Goker-Alpan</surname>
              <given-names>O</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The neurobiology of glucocerebrosidase-associated parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow</article-title>
          <source>Brain</source>
          <year>2012</year>
          <volume>135</volume>
          <fpage>2440</fpage>
          <lpage>2448</lpage>
          <pub-id pub-id-type="pmid">22843412</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schindlbeck</surname>
              <given-names>KA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>LRRK2 and GBA Variants Exert Distinct Influences on Parkinson’s Disease-Specific Metabolic Networks</article-title>
          <source>Cereb. Cortex</source>
          <year>2020</year>
          <volume>30</volume>
          <fpage>2867</fpage>
          <lpage>2878</lpage>
          <pub-id pub-id-type="pmid">31813991</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thaler</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Altered reward-related neural responses in non-manifesting carriers of the Parkinson disease related LRRK2 mutation</article-title>
          <source>Brain Imaging Behav.</source>
          <year>2019</year>
          <volume>13</volume>
          <fpage>1009</fpage>
          <lpage>1020</lpage>
          <pub-id pub-id-type="pmid">29971685</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thaler</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Intact working memory in non-manifesting LRRK2 carriers-an fMRI study</article-title>
          <source>Eur. J. Neurosci.</source>
          <year>2016</year>
          <volume>43</volume>
          <fpage>106</fpage>
          <lpage>112</lpage>
          <pub-id pub-id-type="pmid">26536050</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bregman</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A cognitive fMRI study in non-manifesting LRRK2 and GBA carriers</article-title>
          <source>Brain Struct. Funct.</source>
          <year>2017</year>
          <volume>222</volume>
          <fpage>1207</fpage>
          <lpage>1218</lpage>
          <pub-id pub-id-type="pmid">27401793</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <mixed-citation publication-type="other">Lebedev, A. V. et al. Large-scale resting state network correlates of cognitive impairment in Parkinson’s disease and related dopaminergic deficits. <italic>Front. Syst. Neurosci</italic>. <bold>8</bold>, 00045 (2014).</mixed-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rieckmann</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gomperts</surname>
              <given-names>SN</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Growdon</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Van Dijk</surname>
              <given-names>KRA</given-names>
            </name>
          </person-group>
          <article-title>Putamen-midbrain functional connectivity is related to striatal dopamine transporter availability in patients with Lewy body diseases</article-title>
          <source>Neuroimage Clin.</source>
          <year>2015</year>
          <volume>8</volume>
          <fpage>554</fpage>
          <lpage>559</lpage>
          <pub-id pub-id-type="pmid">26137443</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Blesa</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Compensatory mechanisms in Parkinson’s disease: Circuits adaptations and role in disease modification</article-title>
          <source>Exp. Neurol.</source>
          <year>2017</year>
          <volume>298</volume>
          <fpage>148</fpage>
          <lpage>161</lpage>
          <pub-id pub-id-type="pmid">28987461</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Adams</surname>
              <given-names>JR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>PET in LRRK2 mutations: comparison to sporadic Parkinson’s disease and evidence for presymptomatic compensation</article-title>
          <source>Brain</source>
          <year>2005</year>
          <volume>128</volume>
          <fpage>2777</fpage>
          <lpage>2785</lpage>
          <pub-id pub-id-type="pmid">16081470</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Artzi</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>DaT-SPECT assessment depicts dopamine depletion among asymptomatic G2019S LRRK2 mutation carriers</article-title>
          <source>PLoS One</source>
          <year>2017</year>
          <volume>12</volume>
          <fpage>e0175424</fpage>
          <pub-id pub-id-type="pmid">28406934</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wile</surname>
              <given-names>DJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies</article-title>
          <source>Lancet Neurol.</source>
          <year>2017</year>
          <volume>16</volume>
          <fpage>351</fpage>
          <lpage>359</lpage>
          <pub-id pub-id-type="pmid">28336296</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Djaldetti</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ziv</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Melamed</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>The mystery of motor asymmetry in Parkinson’s disease</article-title>
          <source>Lancet Neurol.</source>
          <year>2006</year>
          <volume>5</volume>
          <fpage>796</fpage>
          <lpage>802</lpage>
          <pub-id pub-id-type="pmid">16914408</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shigekiyo</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Arawaka</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Laterality of specific binding ratios on DAT-SPECT for differential diagnosis of degenerative parkinsonian syndromes</article-title>
          <source>Sci. Rep.</source>
          <year>2020</year>
          <volume>10</volume>
          <fpage>15761</fpage>
          <pub-id pub-id-type="pmid">32978422</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Muller</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Hypertension and longitudinal changes in cerebral blood flow: the SMART-MR study</article-title>
          <source>Ann. Neurol.</source>
          <year>2021</year>
          <volume>71</volume>
          <fpage>825</fpage>
          <lpage>833</lpage>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Specht</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Current challenges in translational and clinical fMRI and future directions</article-title>
          <source>Front Psychiatry</source>
          <year>2020</year>
          <volume>2019</volume>
          <fpage>00924</fpage>
        </element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Goetz</surname>
              <given-names>CG</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results</article-title>
          <source>Mov. Disord.</source>
          <year>2008</year>
          <volume>23</volume>
          <fpage>2129</fpage>
          <lpage>2170</lpage>
          <pub-id pub-id-type="pmid">19025984</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nasreddine</surname>
              <given-names>ZS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment</article-title>
          <source>J. Am. Geriatr. Soc.</source>
          <year>2005</year>
          <volume>53</volume>
          <fpage>695</fpage>
          <lpage>699</lpage>
          <pub-id pub-id-type="pmid">15817019</pub-id>
        </element-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Levin</surname>
              <given-names>BE</given-names>
            </name>
            <name>
              <surname>Llabre</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Weiner</surname>
              <given-names>WJ</given-names>
            </name>
          </person-group>
          <article-title>Parkinson’s disease and depression: psychometric properties of the Beck Depression Inventory</article-title>
          <source>J. Neurol. Neurosurg. Psychiatry</source>
          <year>1988</year>
          <volume>51</volume>
          <fpage>1401</fpage>
          <lpage>1404</lpage>
          <pub-id pub-id-type="pmid">3236018</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Storch</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Quantitative assessment of non-motor fluctuations in Parkinson’s disease using the Non-Motor Symptoms Scale (NMSS)</article-title>
          <source>J. Neural Transm. (Vienna)</source>
          <year>2015</year>
          <volume>122</volume>
          <fpage>1673</fpage>
          <lpage>1684</lpage>
          <pub-id pub-id-type="pmid">26264174</pub-id>
        </element-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Visser</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Marinus</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Stiggelbout</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Van Hilten</surname>
              <given-names>JJ</given-names>
            </name>
          </person-group>
          <article-title>Assessment of autonomic dysfunction in Parkinson’s disease: the SCOPA-AUT</article-title>
          <source>Mov. Disord.</source>
          <year>2004</year>
          <volume>19</volume>
          <fpage>1306</fpage>
          <lpage>1312</lpage>
          <pub-id pub-id-type="pmid">15390007</pub-id>
        </element-citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nomura</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Inoue</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kagimura</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Uemura</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Nakashima</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Utility of the REM sleep behavior disorder screening questionnaire (RBDSQ) in Parkinson’s disease patients</article-title>
          <source>Sleep. Med</source>
          <year>2011</year>
          <volume>12</volume>
          <fpage>711</fpage>
          <lpage>713</lpage>
          <pub-id pub-id-type="pmid">21700495</pub-id>
        </element-citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Doty</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Frye</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Agrawal</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
          <article-title>Internal consistency reliability of the fractionated and whole University of Pennsylvania Smell Identification Test</article-title>
          <source>Percept. Psychophys.</source>
          <year>1989</year>
          <volume>45</volume>
          <fpage>381</fpage>
          <lpage>384</lpage>
          <pub-id pub-id-type="pmid">2726398</pub-id>
        </element-citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Heinzel</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Update of the MDS research criteria for prodromal Parkinson’s disease</article-title>
          <source>Mov. Disord.</source>
          <year>2019</year>
          <volume>34</volume>
          <fpage>1464</fpage>
          <lpage>1470</lpage>
          <pub-id pub-id-type="pmid">31412427</pub-id>
        </element-citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mirelman</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Application of the Movement Disorder Society prodromal criteria in healthy G2019S-LRRK2 carriers</article-title>
          <source>Mov. Disord.</source>
          <year>2018</year>
          <volume>33</volume>
          <fpage>966</fpage>
          <lpage>973</lpage>
          <pub-id pub-id-type="pmid">29603409</pub-id>
        </element-citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Salas-Gonzalez</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Górriz</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Ramírez</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Illán</surname>
              <given-names>IA</given-names>
            </name>
            <name>
              <surname>Lang</surname>
              <given-names>EW</given-names>
            </name>
          </person-group>
          <article-title>Linear intensity normalization of FP-CIT SPECT brain images using the α-stable distribution</article-title>
          <source>Neuroimage</source>
          <year>2013</year>
          <volume>65</volume>
          <fpage>449</fpage>
          <lpage>455</lpage>
          <pub-id pub-id-type="pmid">23063448</pub-id>
        </element-citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koh</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Quantitative reference value of dopamine transporter single‐photon emission computed tomography in healthy Japanese older adults</article-title>
          <source>Neurol. Clin. Neurosci.</source>
          <year>2016</year>
          <volume>4</volume>
          <fpage>215</fpage>
          <lpage>219</lpage>
        </element-citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nobili</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Automatic semi-quantification of [123I]FP-CIT SPECT scans in healthy volunteers using BasGan version 2: results from the ENC-DAT database</article-title>
          <source>Eur. J. Nucl. Med Mol. Imaging</source>
          <year>2013</year>
          <volume>40</volume>
          <fpage>565</fpage>
          <lpage>573</lpage>
          <pub-id pub-id-type="pmid">23232506</pub-id>
        </element-citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Calhoun</surname>
              <given-names>VD</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>fMRI activation in a visual-perception task: network of areas detected using the general linear model and independent components analysis</article-title>
          <source>Neuroimage</source>
          <year>2001</year>
          <volume>14</volume>
          <fpage>1080</fpage>
          <lpage>1088</lpage>
          <pub-id pub-id-type="pmid">11697939</pub-id>
        </element-citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Szewczyk-Krolikowski</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Functional connectivity in the basal ganglia network differentiates PD patients from controls</article-title>
          <source>Neurology</source>
          <year>2014</year>
          <volume>83</volume>
          <fpage>208</fpage>
          <lpage>214</lpage>
          <pub-id pub-id-type="pmid">24920856</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
